Handelsbanken Fonder’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Handelsbanken Fonder’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.34M	Buy	+21,000	New	+$1.09M	﹤0.01%	997

Other funds holding KNSA

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

FEG

Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

JWS

Juncture Wealth Strategies Scottsdale, Arizona $384M AUM 27.62% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

PAS

Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return

Handelsbanken Fonder's KNSA Position: Q2 2026 in Review

Handelsbanken Fonder opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 21,000 shares worth $1.34M. The stake represents ﹤0.01% of the portfolio and ranks #997 among its holdings.

43 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Handelsbanken Fonder held 21,000 shares of Kiniksa Pharmaceuticals worth $1.34M as of Q2 2026.
Kiniksa Pharmaceuticals was a new Handelsbanken Fonder position in Q2 2026.
Kiniksa Pharmaceuticals made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #997 holding.
43 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.